OCULUS Keratograph 5M debuts colour to topography!

Article

Keratograph 5M technology is a revolution in corneal topography and dry eye analysis. The high-resolution colour camera and the integrated magnification changer offer a new perspective on the tear film assessment procedure.

The new Keratograph 5M is the perfect tool for topography and advanced external imaging for dry eye screening.

  • High-resolution colour camera and magnification changer
  • Imaging of the upper and lower meibomian glands
  • Non-invasive tear film break up time and tear meniscus height measurements
  • Assessment of the lipid layer and tear film particles
  • Grading of the bulbar redness
  • Image and video documentation

The high-resolution colour camera and the integrated magnification changer of the OCULUS Keratograph 5M offer a new perspective on the tear film assessment procedure.

The Keratograph 5M provides the ideal illumination for every application: white diodes for the assessment of tear film particles movement, blue diodes for fluorescein imaging, infrared diodes for meibography and white annular illumination is used to precisely measure thousands of points on the surface of the cornea.

In addition to these unique features the Keratograph 5M measures corneal topography precisely. The built-in real keratometer and automatic measurement activation guarantee perfect reproducibility of K values. Tear film break-up time measurement with the Keratograph 5M is touch-free and fully automatic.

Integrate the Keratograph 5M into your practice as an active patient consultation tool. Thanks to many visual maps and easy to understand diagrams the Keratograph 5M enhances communication with your patients.

Further information may be found here.

Company DetailsE-mail: export@oculus.deWebsite: www.oculus.de

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.